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Abstract 
 383 tablets of a pharmaceutical product were analysed by backscatter and 
transmission Raman spectrometry to determine the concentration of an active 
pharmaceutical ingredient (API), chlorpheniramine maleate, at the 2% m/m (4 mg) level. 
As the exact composition of the tablets was unknown, external calibration samples were 
prepared from chlorpheniramine maleate and microcrystalline cellulose (Avicel) of 
different particle size. The API peak at 1594 cm
-1
 in the 2
nd
 derivative Raman spectra was 
used to generate linear calibration models. The API concentration predicted using 
backscatter Raman measurements was relatively insensitive to the particle size of Avicel. 
With transmission, however, particle size effects were greater and accurate prediction of 
the API content was only possible when the photon propagation properties of the 
calibration and sample tablets were matched. Good agreement was obtained with HPLC 
analysis when matched calibration tablets were used for both modes. When the 
calibration and sample tablets are not chemically matched, spectral normalisation based 
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on calculation of relative intensities cannot be used to reduce the effects of differences in 
physical properties. The main conclusion is that although better for whole tablet analysis, 
transmission Raman is more sensitive to differences in the photon propagation properties 
of the calibration and sample tablets. 
 3 
Introduction 
Analysis of tablets is an important part of quality control in pharmaceutical 
manufacturing. Near infrared spectrometry (NIRS) has proved useful for this assay,
1
 but 
in recent years there has been a growing interest in Raman spectrometry for tablet 
analysis owing to the greater chemical specificity, larger penetration depths into the 
sample and sharper spectral features compared to NIRS. Furthermore, common non-
aromatic, non-crystalline excipients are generally poor Raman scattering materials in 
comparison to active drug substances that are often small aromatic heterocycles. 
Identifying active pharmaceutical ingredient (API) peaks, even if present in very low 
concentrations compared to the excipient, is therefore more likely to be achieved with 
Raman spectrometry, than with NIR spectrometry.
2
 
Conventional backscatter Raman spectrometry, typically using laser beam 
diameters of 50 – 500 m, has been used for the composition monitoring of 
pharmaceutical tablets.
2-17
 In many applications, advantages have been demonstrated over 
alternative techniques, often for determination of high relative concentrations of the 
analyte (up to 90%). However, a number of authors have reported that the small volume 
of the tablet sampled by conventional Raman spectrometry can affect the accuracy and 
precision of the analysis.
3, 7, 14
 In a number of studies, a rotating sample holder
6-7, 10-11, 13, 
15, 17
 or multiple-point irradiation
7, 14, 16
 was employed to increase the sampling area and 
hence, improve the repeatability of the Raman measurements. In an on-line example, the 
sampling area was increased by measuring a stream of tablets moving underneath the 
Raman probe on a conveyor system.
17
 Kim et al. reported the advantages of wide area 
illumination for backscatter Raman analysis of pharmaceutical tablets.
18
 The study 
compared the performance of a Raman system that produced a 6 mm diameter spot size 
with that of a conventional Raman system with a 100 µm spot size, to determine 
naproxen in tablets over the concentration range of 58-79% m/m. When replicate 
measurements were made on the same tablet using both methods, a significant 
improvement in the repeatability of the analyte peak area was seen with the larger spot 
size. Wide area illumination Raman analysis was also shown to be successful for the 
quantitative measurement of the API in an intact capsule formulation.
19
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Although an improvement over conventional optical configurations that employ a 
small laser spot size, wide area backscatter Raman spectrometry does not analyse the 
whole tablet. Matousek and Parker demonstrated that with a sample spot size of 4 mm, 
88% of the backscatter Raman signal from a 4 mm thick tablet was generated in the top 
1 mm layer and only 12% of the signal originated from the remaining 3 mm of sample.
20
 
Hence, backscatter Raman spectra of APIs can be dominated by Raman or fluorescence 
signals arising from the tablet coating or capsule.
21-24
 Research into Raman photon 
migration
25-26
 and novel sampling configurations
27-28
 has revealed that many of the 
problems associated with backscatter Raman are removed when transmission Raman is 
used, and the attributes of the technique for analysis of pharmaceutical tablets and 
capsules are now being demonstrated.
20, 22, 24, 29-32
 The absence of sub-sampling 
limitations in transmission Raman spectroscopy has been illustrated by numerical 
simulations
20
 and experimental investigations.
20, 33-36
 Matousek and Parker showed that 
when a 0.5 mm thick inter-layer was moved from the sample surface to a depth of 3 mm 
within a tablet medium, the simulated backscatter Raman signal decreased by four orders 
of magnitude.
20
 In comparison, numerical
20, 34
 and experimental
34-36
 investigations 
showed that the signal was only weakly dependent on the depth of the inter-layer in 
transmission mode; a reduction in signal was observed when the inter-layer was located 
at the sample surface owing to loss of laser and Raman photons at the air-sample 
interface. Elimination of the sub-sampling problem in transmission mode measurements 
has also been illustrated experimentally using two-layer tablets.
20, 33
 While backscatter 
Raman spectra were dominated by signals from the material that was irradiated directly 
by the laser, transmission Raman spectra contained signals from the two materials for 
both tablet orientations. 
There have been some reported applications of transmission Raman spectrometry 
for quantification of an API in pharmaceutical tablets. In most cases, the calibration and 
sample tablets had the same composition and physical properties, which simplified the 
analysis. Johansson et al.
30
 analysed 20 test tablets (3.3 mm thick) that contained API 
concentrations between 16 and 24% m/m. Spectra were preprocessed using a standard 
normal variate (SNV) transformation to normalise the spectra and correct for baseline 
offsets. A laser excitation wavelength of 785 nm and a spot size of 6 mm in diameter 
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were used and the study concluded that transmission Raman had the potential to give 
simpler more robust calibration models compared with backscatter Raman. This was 
primarily attributed to the more representative measurements achieved with transmission 
Raman, which resulted in a lower prediction error and the requirement for fewer partial 
least squares (PLS) components to explain the variance of the data. In a subsequent 
study,
37
 different multivariate methods were used to analyse transmission Raman data 
acquired of paracetamol tablets. Owing to the high spectral selectivity and bulk sampling 
properties of transmission Raman, it was possible to construct calibration models (PLS, 
multivariate curve resolution or classical least squares) using a reduced number of 
calibration samples as well as with fewer components. The simpler calibration 
requirements of transmission Raman spectrometry, compared to NIRS, offer considerable 
opportunities for deployment in drug development. 
Eliasson et al.
29
 demonstrated the advantages of transmission Raman over the 
backscatter mode for the determination of 27 – 33% m/m concentrations of an API 
contained within capsules, which gave rise to a strong interfering Raman signal (mainly 
TiO2). The signal from the capsule shell relative to that from the API was significantly 
reduced with transmission measurements and a root mean square error of prediction of 
1.2% was achieved for the API with a 5 s acquisition time. Hargreaves et al.
31
 used 
transmission Raman measurements to quantify the concentration of API (approx. 75% 
m/m) in a formulation containing three excipients in capsules of different sizes and fill 
level. Spectra were baseline corrected and normalised to unit length to account for 
variations in the transmission Raman signal intensity arising from differences in the 
amount of material within the capsules. Consequently, it was possible to use a PLS model 
developed using 100 mg capsules to predict the API content in 100 – 400 mg capsules 
with a relative error of less than 3%. 
Recently, transmission and backscatter Raman spectrometries were compared for 
quantification of two polymorphic forms (I and III) of flufenamic acid.
38
 Spectra were 
pre-processed using a multiplicative scatter correction. Measurements made in the 
backscatter mode were highly variable and over-estimated the amount of form III in 
mixtures of the two polymorphs. The high variability in the Raman signal was due to the 
inherent sub-sampling issue associated with backscatter measurements. Over-estimation 
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of the amount of form III arose as a result of surface segregation of the two polymorphs 
and the bias of backscatter measurements towards the surface. In comparison, 
transmission measurements were not affected by any sub-sampling issues and so 
provided an accurate method for quantification of the two polymorphs. 
The aforementioned studies indicate that Raman spectrometry, particularly in the 
transmission mode, is well suited for the quantitative, non-invasive analysis of 
pharmaceutical tablets. Most of the reported applications have concerned determination 
of API concentrations in excess of 10% m/m and the number of tablets analysed has 
generally been 20 or less, and often involved simulated samples. In this study, a large 
number (383) of tablets of a commercially available pharmaceutical product has been 
analysed by backscatter and transmission Raman spectrometry to determine the 
concentration of an API at the 2% m/m level. In previous studies comparing the 
performance of backscatter and transmission Raman spectrometries, the calibration and 
sample tablets were generally matched. However, in one study
31
 where the amount of 
material analysed was varied but the chemical composition of the calibration and sample 
tablets was matched, it was possible to use spectral normalisation to unit length to render 
the transmission measurement insensitive to the amount of material. When the full 
composition of the samples is unknown, it is not possible to use matched calibration 
standards. In this case, the aforementioned normalisation procedure based on calculation 
of relative intensities cannot be used to correct for possible differences in the photon 
propagation properties of the calibration and sample tablets. In the present study, external 
calibration tablets that were not matched to the composition of the sample tablets were 
prepared from different particle size distributions of microcrystalline cellulose and 
chlorpheniramine maleate, which produced calibration tablets with different photon 
propagation properties. The susceptibility of backscatter and transmission Raman 
analysis to such variations in the physical properties of sample and calibration tablets, 
which may arise when external calibration tablets are used, was compared. This type of 
assessment has not been previously reported. 
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Experimental 
Materials 
Chlortrimeton antihistamine over-the-counter tablets (Schering-Plough 
HealthCare Products, Inc., Memphis, TN, USA) were purchased from a pharmacy. The 
tablets came from the same manufactured batch and nominally contained 4 mg (about 
2% m/m) chlorpheniramine maleate (the API), corn starch, D&C yellow No 6 & 10, 
lactose monohydrate and magnesium stearate, although the exact composition of the 
samples was unknown. 
Chlorpheniramine maleate (99.8% purity), reagent grade ammonium acetate, 
HPLC grade acetonitrile and reagent grade glacial acetic acid were purchased from 
Sigma Aldrich, USA. Microcrystalline cellulose (Avicel PH-101, 105 and 200) was 
provided by GSK, Irvine, UK. The particle size information (D10 – D90 and D50) for each 
grade of Avicel has been reported as:
39
 PH-101: 20.5 – 140.9 µm and 61.7 µm; PH-105: 
4.5 – 36.0 µm and 16.3 µm; PH-200: 41.1 – 333.8 µm and 178.0 µm. 
 
High performance liquid chromatography (HPLC) 
A Waters 660 pump with a 626S controller, in-line degasser, 717 autosampler and 
diode array detector were used. Data were acquired and processed using Waters 
Empower software. Separation was achieved with an Agilent column (C18, 4.6 mm × 
150 mm, 5 μm particle size) operated at ambient temperature (20 – 23 C). The mobile 
phase was an 80:20 mix of 25 mM ammonium acetate and acetonitrile, adjusted to pH 5.5 
using glacial acetic acid. 
Seven solutions of chlorpheniramine maleate (covering the range 0 – 240 mg L-1) 
were prepared in the mobile phase for calibration of the instrument response. Tablets 
were crushed and the powder dissolved in mobile phase and diluted to 25 mL. As the 
intended mass of chlorpheniramine maleate in each tablet is 4 mg, the concentration of 
chlorpheniramine maleate in the sample solutions was about 160 mg L
-1
. Solutions were 
sonicated for five minutes and then filtered using 0.2 μm disposable Acrodisc filters 
(Sigma Aldrich, USA) before injecting 20 μL for analysis. The chromatogram recorded at 
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254 nm revealed the analyte peak at 1.71 min and two excipient peaks at 10 and 
12.5 min. The relative standard deviation (RSD) of the analyte peak areas for six replicate 
injections of a 160 mg L
-1
 chlorpheniramine maleate standard solution was 0.93%. The 
calibration response curve for chlorpheniramine maleate was linear over the range 0 – 
240 mg L
-1
 (R
2
 = 0.9986). 
 
Raman spectrometry 
A Kaiser Raman Workstation and PhAT probe (Kaiser Optical systems, Ann 
Arbor, USA) were used for tablet analysis in the backscatter and transmission modes. An 
Invictus diode laser was employed, which has a wavelength of 785 nm and was operated 
at 400 mW at the source. For backscatter measurements, the tablets were illuminated 
from above using the PhAT probe with a laser beam optically expanded to give a 3 mm 
spot size. For transmission measurements, the tablets were illuminated from below using 
a laser spot that had been expanded to 3 mm diameter and transmitted Raman photons 
were collected from a 3 mm diameter circular region on the upper surface of the tablet 
directly above the illumination point. Raman spectra were obtained with a 20 s exposure 
time and 3 acquisitions for backscatter measurements, and a 60 s exposure time and 3 
acquisitions for transmission measurements. A dark current spectrum was acquired 
before each set of experiments and the HoloGRAMS operating software subtracted the 
dark current from each sample spectrum acquired. The spectra were then converted to 
text files and imported into Matlab version 7.0.2 (Mathworks Inc., Natick, Massachusetts, 
USA) for analysis using the PLS_Toolbox version 3.0.4 (Eigenvector Research Inc., 
Manson, Washington, USA). Second derivative spectra were calculated using the 
Savitzky-Golay function with a 51 point filter width and second order polynomial. 
Calibration tablets containing known concentrations of chlorpheniramine maleate 
were prepared for direct analysis of the Chlortrimeton tablets. As the detailed 
composition of the sample tablets could not be obtained from the manufacturer, 
microcrystalline cellulose (Avicel) was used to produce the calibration tablets as it did 
not interfere with the spectral region of interest (Figure 1). Avicel and chlorpheniramine 
maleate were blended for 10 min in a tumbler blender and then tablets were pressed for 
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Figure 1. Raman spectra of a) a Chlortrimeton tablet (backscatter), b) a powdered sample 
of chlorpheniramine maleate (backscatter), c) a Chlortrimeton tablet (transmission, signal 
multiplied by 6) and d) a sample of Avicel PH-101 powder (transmission, signal 
multiplied by 6). 
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each analyte concentration. The calibration tablets were weighed to estimate the mass of 
chlorpheniramine maleate in each tablet, assuming that a homogeneous blend had been 
produced. Six tablets covering the range 0 – 8 mg of chlorpheniramine maleate per tablet 
were used for analysis of 383 Chlortrimeton tablets by backscatter and transmission 
Raman measurements. 
Calibration plots were produced using the intensity of the chlorpheniramine 
maleate peak at 1594 cm
-1
, from both sides of each tablet, scaled to account for 
fluctuations in laser power. The scaling factor for each spectrum was calculated from the 
intensity of the Avicel peak at 1095.5 cm
-1
 in the 2
nd
 derivative spectrum of the first 
calibration tablet analysed divided by the Avicel peak intensity in the spectrum of 
subsequent calibration tablets. All the calibration plots had R
2 
values between 0.98 and 
0.99. Similarly, the intensity of the chlorpheniramine maleate peak in the Chlortrimeton 
tablets was scaled using the lactose
40
 excipient peak at 1142.5 cm
-1
 in the 2
nd
 derivative 
spectrum of the first tablet analysed divided by the lactose peak intensity in the spectrum 
of subsequent sample tablets. The scaled peak intensities were then used to calculate the 
mass of chlorpheniramine maleate in the Chlortrimeton tablets. 
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Results 
HPLC analysis 
254 tablets were individually weighed and analysed to determine the mass of 
chlorpheniramine maleate in each tablet. A summary of the results is given in Table 1 and 
histograms of tablet mass and amount of chlorpheniramine maleate are shown in Figures 
2a and 2b, respectively. The mean amount of 3.98 mg chlorpheniramine maleate was 
close to the target value of 4 mg indicated by the manufacturer, but the range was quite 
wide (3.36 to 4.81 mg) and the mass of the tablets also varied more than expected. The 
tablet mass and amount of chlorpheniramine maleate did not always vary proportionally; 
some tablets of higher mass had lower API content and vice versa, such that the 
chlorpheniramine maleate concentration ranged from 1.66 to 3.31% m/m (Figure 2c). 
Skewness and kurtosis statistics show that the data for the tablet mass, and API mass and 
concentration are not normally distributed. The API data are skewed to the right and are 
long tailed, which means that there is an enhanced probability of a tablet containing a 
high API content compared to a normal distribution. As the Chlortrimeton tablets are 
intended to be taken four times daily for a prolonged period, the variation in the amount 
of chlorpheniramine maleate contained in the tablets is of no pharmaceutical 
consequence. The results suggest, however, that better control of the manufacturing 
process could be achieved and in this regard direct spectroscopic analysis at the blending 
and tableting steps has potential advantages over HPLC, which is destructive and time 
consuming. 
 
Raman spectrometry 
Spectra of both sides of a tablet with heterogeneous distribution of chlorpheniramine 
maleate. A calibration tablet was prepared with a heterogeneous distribution of 
chlorpheniramine maleate (6.59 mg in a mass of Avicel corresponding to 4.95% m/m 
analyte) and both sides of the tablet were analysed by backscatter and transmission 
Raman spectrometry. The spectra in Figure 3a show that in the backscatter mode, the 
heterogeneous distribution of chlorpheniramine maleate results in spectra of different 
intensity from the two sides of the tablet. In contrast, the transmission mode spectra 
 12 
 
Table 1. Summary of maximum, minimum, mean, %RSD, skewness and kurtosis values 
of the tablet mass, and chlorpheniramine maleate mass and concentration for 254 
Chlortrimeton tablets. 
 tablet mass 
Chlorpheniramine maleate 
mass 
Chlorpheniramine maleate 
concentration 
Mean 201.4 mg 3.98 mg 1.98% m/m 
Minimum 118.5 mg 3.36 mg 1.57% m/m 
Maximum 250.7 mg 4.81 mg 3.31% m/m 
%RSD 6.1 6.3 8.8 
Skewness
a 
-0.91 1.06 1.99 
Kurtosis
a 
12.43 5.01 15.45 
 
a
 Skewness and kurtosis statistics were calculated using the third and fourth standardised 
moments, respectively.
41
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Figure 2. Histograms of a) tablet mass, b) chlorpheniramine maleate (API) mass and c) 
chlorpheniramine maleate (API) concentration (n=254). 
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Figure 3. Second derivative Raman spectra of both sides of a microcrystalline cellulose 
based tablet (Avicel PH-101) showing the chlorpheniramine maleate peak at 1594 cm
-1
 in 
the a) backscatter and b) transmission modes. 
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(Figure 3b) are more similar in intensity. Backscatter Raman maps acquired of both sides 
of the tablet using the PhAT probe showed that one surface of the tablet was rich in 
chlorpheniramine maleate whereas the other side was predominantly excipient. Hence, 
the results obtained are similar to those reported for the analysis of two-layer tablets 
using backscatter and transmission Raman measurements.
20, 33
 It can be concluded that 
backscatter Raman is better at indicating differences in the amount of a compound on 
different sides of a tablet (i.e. heterogeneity), whereas transmission Raman should be 
better for whole tablet quantitative analysis. 
 
Analysis of Chlortrimeton tablets using external calibration tablets. A second set of 383 
Chlortrimeton tablets were analysed by backscatter and transmission Raman 
spectrometry using calibration tablets prepared with Avicel PH-101 microcrystalline 
cellulose (D50 of 61.7 μm
39
). The scaled intensity at 1594 cm
-1
 in the 2
nd
 derivative 
spectrum from both sides of each calibration tablet was used to generate the linear 
calibration models. When the sample tablets were analysed by backscatter Raman 
spectrometry, the mean mass of chlorpheniramine maleate was 3.87 mg with a RSD of 
3.3%, in good agreement with the results obtained by HPLC for the first set of 254 
Chlortrimeton tablets. However, with transmission Raman spectrometry the mean mass 
derived from the calibration model was 8.70 mg with a RSD of 5.4%, which suggests that 
there is a difference in the propagation of the Raman photons through the sample and 
calibration tablets caused by their different composition. 
To investigate the effect of particle size on the backscatter and transmission 
Raman signals of chlorpheniramine maleate, additional calibration tablets were prepared 
from Avicel PH-105 and Avicel PH-200 that have D50 values of 16.3 and 178.0 μm, 
respectively.
39
 The average mass of the API predicted by backscatter and transmission 
Raman spectrometry using the calibration tablets prepared from each grade of Avicel are 
shown in Table 2. The effect of the particle size of Avicel on the accuracy of the 
estimated mass of chlorpheniramine maleate in the Chlortrimeton tablets is much greater 
for the transmission Raman measurements than for backscatter Raman. The calibration 
tablets made using Avicel PH-200 gave the most accurate prediction of chlorpheniramine 
maleate by transmission Raman suggesting that the photon transmission properties of 
 16 
 
Table 2. Comparison of the average predicted mass of chlorpheniramine maleate and % 
RSD values obtained for backscatter and transmission Raman measurements at 1594 cm
-1
 
in 2
nd
 derivative spectra when calibration tablets containing different Avicel grades are 
used; n = 383; expected mass 4 mg. 
Grade of 
Avicel 
Backscatter Raman Transmission Raman 
 Average mass/mg %RSD Average mass/mg %RSD 
PH-105 4.32 3.5 7.33 5.6 
PH-101 3.87 3.3 8.70 5.4 
PH-200 3.64 3.6 3.95 5.8 
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these tablets match best those of the Chlortrimeton tablets. This does not necessarily 
mean that the sample and Avicel PH-200 have similar particle sizes, only similar photon 
transmission efficiency, which may arise for a number of reasons. Although the Avicel 
particle size effects on the backscatter Raman measurements are less pronounced than for 
transmission Raman, there are some differences with the PH-101 grade giving the best 
estimate of the chlorpheniramine maleate content of the Chlortrimeton tablets. 
The relative insensitivity of wide area backscatter measurements to differences in 
particle size between the calibration and sample tablets is consistent with previous 
findings.
42
 Hu et al. attributed the insensitivity of wide area (3 mm laser spot size) 
backscatter Raman measurements, compared to measurements made using a 60 m laser 
spot size, to the increased sampling volume being much greater than the sample particle 
size.
42
 Although the sampling volume of transmission Raman measurements far exceeds 
that of backscatter Raman measurements, which are dominated by the initial 1 mm or so 
of a tablet,
20
 previous studies have shown that the propagation of photons in the 
transmission mode is significantly affected by variations in the size and type of 
particles.
36, 43
 The relatively minor effect of particle size on the backscatter Raman 
spectra arises because most of the signal originates from the surface.
20
 Particle size 
affects the surface smoothness and it may be that this is best matched to the sample 
tablets in this study when the calibration tablets are prepared from Avicel PH-101. 
In previous studies where the chemical composition and the physical properties of 
the sample and calibration tablets were matched, any effects of variations in the amount 
of material measured on the transmission Raman signal were reduced through 
normalisation procedures based on calculation of relative intensities. Although it is 
generally best to matrix-match the sample and calibration tablets, this is not always 
possible, especially if the sample tablet composition is not known accurately. This part of 
the study demonstrated that although transmission Raman measurements are more 
representative of the whole sample, in contrast to backscatter, it is more likely that 
inaccurate estimations of the analyte mass/concentration will arise if the external 
calibration set is not well matched to the sample set in terms of photon propagation 
characteristics. This is a conclusion that has not been mentioned in previous studies of 
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transmission Raman spectrometry. Addition of an internal standard can mitigate against 
matrix differences between samples and calibrants, but is generally destructive
10
 and not 
suitable for direct analysis of tablets.  
 
Comparison of Raman and HPLC analyses 
A sub-set of 25 Chlortrimeton tablets analysed by both Raman modes was also 
analysed using the HPLC method to allow a direct comparison of the performance of the 
techniques on the same sample set. The results for backscatter and transmission Raman 
were obtained with the PH-101 and PH-200 Avicel calibration tablets, respectively. The 
mean mass of chlorpheniramine maleate ± 1 standard deviation obtained by HPLC, 
backscatter and transmission Raman, respectively, was 3.85 ± 0.11, 3.92 ± 0.20 and 
4.02 ± 0.24 mg. Through the use of the F-test and Student’s t-test, it was shown that there 
were no statistical differences at the 95% confidence interval between the average values 
obtained by the two Raman methods and between backscatter Raman and HPLC, but 
there were statistical differences between the results obtained by transmission Raman and 
HPLC. 
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Conclusions 
Previous work by the authors has shown that the physical properties of a powder 
(e.g. particle size) have a significant effect on the propagation of laser and Raman 
photons generated in the transmission mode.
36
 The results of the present investigation 
illustrate the analytical consequences of these prior observations for the analysis of 
tablets. It has been shown that transmission Raman spectrometry can be used to quantify 
accurately the content of chlorpheniramine maleate at the 2% m/m level in a 
pharmaceutical tablet product when external calibration tablets are prepared from 
microcrystalline cellulose (Avicel), provided the photon propagation characteristics of the 
sample and calibration tables are matched. Backscatter Raman can also be used 
successfully for this analysis and is less susceptible to particle size effects. In previous 
Raman studies, the effects of physical properties such as particle size were either not 
explored or considered to be less significant than for near infrared spectrometry.
32
 This 
study indicates that this is not the case. Nonetheless, both Raman methods have 
advantages over HPLC which is often the standard method for API analysis, but it takes 
longer and involves destruction of the sample tablets.  
If preparation of calibration tablets with photon propagation properties similar to 
the samples is not easily achieved, a reference method such as HPLC could be used to 
construct calibration models for the Raman analysis. However, it is likely that the API 
would need to be added to a selection of sample tablets to extend the calibration range as 
the mass range of API in commercial samples is normally relatively small. Recently there 
have been some advances in spectral pre-processing procedures for the removal of the 
effects of particle size from Raman spectra acquired in backscatter mode.
44
 Such 
procedures could be extended to provide similar benefits in transmission Raman 
spectrometry, particularly when it is not possible to use calibration and sample tablets 
with the same chemical composition. 
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